Get the Strategy to Trade Pre-Fed Setups and Post-Fed Swings—Live With Chris Capre ... an anti-CD117 monoclonal antibody (mAb), and BEAM-104, a cell therapy that includes the same therapeutic ...

Boston biotech Beam Therapeutics has announced initial data from a phase 1/2 trial of its gene therapy for a genetic lung and liver disease, with no serious adverse events reported among the nine ...

About BEAM-101 BEAM-101 is an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD). The one-time therapy consists of autologous CD34+ hematopoietic stem ...

On Monday, Cambridge, Massachusetts-based Beam said it received an FDA email notifying the company about the clinical hold placed on the application for the therapy, BEAM-201. Beam disclosed ...

Growth Drivers of The Gene Therapy Industry As per IMARC, the US gene therapy market size has been pegged at US$1,312.2 million in 2024. The market should reach US$3,697.8 million by 2033.

On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified ...

underscoring the therapy’s promise and the urgent need for effective AATD solutions. Preliminary data from ongoing Phase 1/2 trials show BEAM-302 is well tolerated and achieves dose-dependent ...